Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
18/03/2025 11:06
March 18 (Reuters) - Bio Path Holdings Inc BPTH.PK: BIO-PATH HOLDINGS ANNOUNCES PRE-CLINICAL RESULTS SIGNALING INCREASED POTENTIAL FOR BP1001-A AS TREATMENT FOR OBESITY IN TYPE 2 DIABETES PATIENTS BIO PATH HOLDINGS INC - PLANS TO FILE IND APPLICATION FOR BP1001-A IN 2025 Source text: ID:nGNXc2pGDL Further company coverage: BPTH.PK ((Reuters.Briefs@thomsonreuters.com))
Recent news on Bio Path Holdings
See all newsBrief: Bio-Path Holdings Seeks Financing For Turnaround & Strategic Actions
Brief: Bio-Path Holdings Reports Full Year 2024 Financial Results
Brief: Bio-Path Holdings Announces Pre-Clinical Results Signaling Increased Potential for BP1001-A as Treatment for Obesity in Type 2 Diabetes Patients
Brief: Bio-Path Provides Key Clinical Updates
Brief: Bio-Path Holdings Provides Update From Phase 1/1B Clinical Trial Of Bp1002 For Treatment Of Refractory/Relapsed Acute Myeloid Leukemia